

Microbiome Sequencing Service Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing by synthesis, Sequencing by ligation, Sanger sequencing, Others), By Application (Autoimmune Disorder, Cancer, Gastrointestinal Disorders, Others), By Region and Competition, 2019-2029F

Market Report | 2024-08-02 | 185 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

Report description:

Global Microbiome Sequencing Service Market was valued at USD 285.24 Million in 2023 and is expected to reach USD 372.54 Million by 2029 with a CAGR of 4.75% during the forecast period. The human microbiome, the collection of microorganisms residing in and on the human body has emerged as a crucial area of research with significant implications for health and disease. Advances in microbiome sequencing have provided deeper insights into how these microbial communities influence various aspects of health, including digestion, immunity, and even mental well-being. This understanding has fueled interest in microbiome analysis, driving demand for sequencing services that can provide comprehensive and detailed microbiome profiles. The growth of the microbiome sequencing service market is significantly supported by technological advancements in sequencing technologies. Next-Generation Sequencing (NGS) has revolutionized microbiome research by offering high-throughput, cost-effective, and accurate sequencing capabilities. This technology enables researchers and clinicians to analyze complex microbial communities with unprecedented detail, facilitating the identification of microbial species and their functional roles. Innovations in bioinformatics tools and data analysis platforms further enhance the ability to interpret vast amounts of sequencing data, contributing to the market's expansion.

Microbiome sequencing services are increasingly being utilized in healthcare to explore the link between microbiome composition and various health conditions. Research indicates that imbalances in the microbiome, known as dysbiosis, are associated with a range of diseases, including inflammatory bowel disease (IBD), obesity, diabetes, and cardiovascular disorders. Microbiome sequencing provides valuable insights into these conditions, enabling the development of personalized treatment strategies and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

probiotic interventions. The growing recognition of the microbiome's role in health and disease drives demand for sequencing services in clinical research and diagnostics.

The consumer wellness sector is a burgeoning area for microbiome sequencing services. Personalized microbiome testing kits allow individuals to gain insights into their gut health, dietary impacts, and potential areas for improvement. These consumer-facing products offer valuable information for optimizing health and wellness, fueling interest and adoption. As consumers become more proactive about their health, the demand for microbiome testing services tailored to individual needs is expected to rise.

Significant investments in research and development (R&D) are propelling the microbiome sequencing service market forward. Academic institutions, research organizations, and pharmaceutical companies are conducting extensive studies to explore the microbiome's role in various physiological processes and diseases. These research activities generate a demand for sequencing services to support investigations into microbial diversity, functional capabilities, and interactions with the host. Funding from government agencies and private entities for microbiome-related research further contributes to market growth.

The microbiome sequencing market is also influenced by regulatory and ethical considerations. Governments and regulatory bodies are establishing guidelines and standards for microbiome research and testing to ensure data accuracy, privacy, and ethical use. Compliance with these regulations is essential for market players to maintain credibility and ensure the responsible use of microbiome data. Regulatory frameworks are evolving to address the complexities of microbiome research, impacting the development and implementation of sequencing services.

The future of the global microbiome sequencing service market is promising, with continued advancements in sequencing technologies, growing applications in healthcare and consumer wellness, and increased investment in research. As the understanding of the microbiome's impact on health deepens, the demand for microbiome sequencing services is expected to rise, driving market growth. The expansion of applications, coupled with technological innovation and supportive regulatory frameworks, will play a crucial role in shaping the future of the microbiome sequencing service market.

Key Market Drivers

Rising Prevalence of Chronic Diseases

Research has increasingly highlighted the critical role that the microbiome—the diverse collection of microorganisms living in and on the human body—plays in maintaining health and influencing disease outcomes. Imbalances in the microbiome, known as dysbiosis, have been associated with a range of chronic diseases. For instance, alterations in gut microbiota have been linked to metabolic disorders like obesity and diabetes, as well as inflammatory conditions such as inflammatory bowel disease (IBD) and cardiovascular diseases. As the understanding of these connections deepens, there is a growing demand for microbiome sequencing services to uncover the underlying mechanisms and develop targeted interventions.

According to a 2022 report by the Australian Bureau of Statistics, 81.4% of individuals reported having at least one long-term health condition, with 49.9% having at least one chronic condition. The most prevalent chronic conditions were mental and behavioral disorders (26.1%), back problems (15.7%), and arthritis (14.5%).

The rising prevalence of chronic diseases is driving advancements in microbiome sequencing technology. Next-Generation Sequencing (NGS) has revolutionized the field by providing high-throughput, accurate, and cost-effective methods for analyzing complex microbial communities. These advancements enable researchers to perform detailed and comprehensive microbiome profiling, which is essential for identifying disease-associated microbial patterns and potential therapeutic targets. The growing need for such detailed analyses in the context of chronic disease management is fueling the demand for sophisticated microbiome sequencing services.

Microbiome sequencing offers valuable diagnostic and therapeutic opportunities for chronic diseases. By identifying specific microbial signatures associated with disease states, healthcare providers can develop more accurate diagnostic tools and personalized treatment plans. For example, understanding the gut microbiome's role in diabetes can lead to targeted dietary and probiotic interventions that help manage blood glucose levels. Similarly, identifying microbial biomarkers for cardiovascular diseases can aid in early detection and prevention. The potential to improve diagnostic accuracy and therapeutic outcomes is a significant driver of the microbiome sequencing service market.

The shift towards personalized medicine is another factor driving the growth of the microbiome sequencing market. Personalized medicine aims to tailor treatments based on an individual's unique genetic and microbial profile. Microbiome sequencing plays a

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

critical role in this approach by providing insights into how an individual's microbiome influences disease risk and treatment response. As personalized medicine gains traction, the demand for microbiome sequencing services that support individualized health strategies is expected to rise.

The rising prevalence of chronic diseases has led to increased investment in research and development (R&D) focused on understanding the microbiome's role in health and disease. Government funding, private investments, and academic research are driving innovation in microbiome sequencing technologies and applications. This investment supports the development of new sequencing methods, bioinformatics tools, and clinical applications, further accelerating market growth.

As the clinical applications of microbiome sequencing become more evident, its integration into routine healthcare practices is increasing. Hospitals, research institutions, and diagnostic laboratories are adopting microbiome sequencing to enhance disease management and treatment efficacy. This integration into clinical workflows is a significant factor contributing to the expansion of the microbiome sequencing service market.

Increasing Research in Microbiome Science

Microbiome science, which studies the diverse communities of microorganisms residing in and on the human body, as well as in various environmental contexts, is uncovering new insights into the roles these microorganisms play in health and disease. Research into the human microbiome has revealed its critical impact on a range of physiological processes, including metabolism, immunity, and mental health. This expanding knowledge base is driving the demand for sophisticated microbiome sequencing services that can provide detailed insights into microbial composition and function.

Recent breakthroughs in microbiome research have demonstrated strong links between microbiome imbalances and conditions such as obesity, diabetes, inflammatory bowel disease (IBD), and even neurodegenerative disorders. These findings underscore the importance of understanding microbiome dynamics and fuel the need for high-resolution sequencing technologies to explore microbial communities in greater depth.

Since 2021, a diverse team of researchers at MIT has been focused on translating new discoveries about the human microbiome into treatments for various diseases. Alm's lab, in collaboration with the Broad Institute of MIT and Harvard, initially conducted pioneering work in characterizing the gut microbiome and elucidating its connection to human health. This foundational research has sparked a surge of interest in microbiome studies, attracting scientists from diverse fields and catalyzing new breakthroughs. Startups are now emerging to develop microbiome-based therapies, while nonprofit organizations have also been established to help translate these scientific advances into treatments that can benefit a broad population.

The rapid advancement of sequencing technologies has significantly contributed to the growth of the microbiome sequencing market. Innovations such as next-generation sequencing (NGS), metagenomics, and high-throughput sequencing have revolutionized microbiome research by providing more detailed and accurate profiles of microbial communities. These technologies enable researchers to analyze complex microbial ecosystems with unprecedented precision, driving demand for advanced sequencing services.

For instance, NGS allows for the comprehensive analysis of microbial DNA, revealing the presence and abundance of various microorganisms within a sample. Metagenomics, on the other hand, provides insights into the functional potential of microbial communities by sequencing their collective genetic material. These technological advancements have broadened the scope of microbiome research and increased the reliance on sequencing services to generate actionable data.

The applications of microbiome research extend beyond basic science into clinical and personalized medicine. Research into the human microbiome is paving the way for novel diagnostic tools, targeted therapies, and personalized health interventions. By understanding individual microbiome profiles, healthcare providers can develop customized treatment plans, improve disease management, and enhance overall patient outcomes.

The rise of personalized medicine, driven by insights from microbiome research, has created a burgeoning demand for microbiome sequencing services. These services are essential for identifying specific microbial signatures associated with health conditions, monitoring treatment responses, and tailoring interventions based on individual microbiome characteristics. Increased funding for microbiome research from government agencies, research institutions, and private organizations has significantly impacted the growth of the microbiome sequencing market. Grants and investments support large-scale studies, clinical trials, and the development of new sequencing technologies. Collaborative research efforts between academic institutions, biotechnology companies, and healthcare providers further drive the advancement of microbiome science and sequencing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

services.

Key Market Challenges

Technical and Methodological Challenges

The global microbiome sequencing service market has experienced significant growth due to increasing interest in understanding microbial communities and their impact on health and disease. Despite its advancements, the market faces substantial technical and methodological challenges that can impact the accuracy, reliability, and overall effectiveness of microbiome sequencing services.

One of the foremost technical challenges in microbiome sequencing is ensuring the quality and integrity of samples. Microbiome samples, which can be derived from diverse sources such as human gut, skin, or environmental environments, are highly sensitive to contamination. Even minor contamination can skew results and undermine the reliability of data.

Contamination can occur at various stages, from sample collection to processing and sequencing. Implementing stringent protocols and quality control measures is essential to prevent contamination and ensure that samples accurately represent the microbial communities of interest. The development and adoption of improved sample handling and processing techniques are critical to addressing this challenge.

The complexity of microbiome data poses a significant challenge for both data management and interpretation. Microbiome sequencing generates vast amounts of data, including information on microbial diversity, abundance, and functional potential. Analyzing this data requires sophisticated bioinformatics tools and expertise.

The diversity and variability within microbial communities add layers of complexity to data interpretation. Accurate analysis involves identifying and characterizing numerous microbial taxa and understanding their interactions and roles within the ecosystem. This requires advanced algorithms and computational resources to manage and make sense of the extensive datasets produced by sequencing technologies.

The lack of standardization in microbiome sequencing methodologies can lead to variability in results between different studies and laboratories. Variations in protocols, such as differences in sample preparation, sequencing techniques, and data analysis methods, can affect the reproducibility and comparability of results.

Standardizing protocols and establishing best practices are crucial for ensuring consistent and reliable outcomes across different studies and settings. Industry-wide consensus on standardized methodologies can help mitigate discrepancies and enhance the reproducibility of microbiome research findings.

The management of large volumes of microbiome data presents a significant challenge. Microbiome sequencing generates extensive datasets that require robust storage solutions and efficient data management systems. Ensuring that data is securely stored, easily accessible, and organized in a way that facilitates analysis is essential for maintaining data integrity and supporting ongoing research.

Advanced data storage solutions and integrated data management platforms are necessary to handle the growing volume of microbiome data. These systems must support the efficient processing and retrieval of data while ensuring compliance with data privacy and security regulations.

Integrating microbiome data with other omics data, such as genomics, proteomics, and metabolomics, can provide a more comprehensive understanding of biological systems. However, combining data from multiple sources introduces additional technical challenges, including data harmonization, integration, and analysis.

Developing methodologies and tools to effectively integrate and analyze multi-omics data is crucial for gaining deeper insights into microbial functions and their interactions with host organisms. Addressing these challenges requires advancements in analytical techniques and interdisciplinary collaboration.

Interpreting microbiome sequencing results requires expertise in microbial ecology and functional genomics. The relationship between microbial composition and health outcomes is complex and not fully understood. Researchers must navigate this complexity to extract meaningful insights from the data and apply them to clinical or research contexts.

Key Market Trends

Growing Demand for Personalized Health Solutions

The global microbiome sequencing service market is witnessing remarkable growth, largely driven by the increasing demand for personalized health solutions. As individuals and healthcare providers alike seek more tailored approaches to health management,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

microbiome sequencing has emerged as a pivotal tool in delivering customized health insights.

Personalized health solutions, often referred to as precision medicine, are designed to tailor medical care and wellness strategies to the unique characteristics of each individual. This approach contrasts with the traditional one-size-fits-all model by considering genetic, environmental, and lifestyle factors to optimize health outcomes. The increasing consumer and healthcare provider interest in personalized health is driving significant growth in the microbiome sequencing service market.

Microbiome sequencing, the process of analyzing the genetic material of microorganisms within a given environment, has become a cornerstone of personalized health. The human microbiome, which consists of trillions of microorganisms residing in and on the body, plays a crucial role in overall health and disease susceptibility. By sequencing an individual's microbiome, healthcare providers can gain insights into microbial composition and function, leading to more precise and effective health interventions. One of the primary applications of microbiome sequencing in personalized health is the development of customized nutritional and lifestyle recommendations. Each individual's microbiome composition affects how they metabolize nutrients, respond to diets, and maintain gut health. Sequencing provides detailed information on an individual's microbiome profile, allowing for tailored dietary advice and lifestyle changes that can enhance health and prevent disease. For example, personalized nutrition plans based on microbiome analysis can help optimize digestion, improve metabolic health, and support weight management.

Microbiome sequencing is also facilitating the development of targeted therapeutics and probiotics. By identifying specific microbial imbalances or deficiencies, healthcare providers can prescribe targeted probiotic supplements or other interventions designed to restore a healthy microbiome balance. This personalized approach to therapy is more effective than generalized treatments, as it addresses the root cause of imbalances unique to each individual's microbiome.

The ability to personalize health solutions extends to disease prevention and management. Microbiome sequencing can identify biomarkers associated with susceptibility to certain diseases, such as inflammatory conditions, diabetes, and cardiovascular diseases. By understanding an individual's risk factors through their microbiome profile, preventive measures and early interventions can be tailored accordingly. This proactive approach helps in managing chronic conditions more effectively and reducing the risk of disease progression.

The increasing consumer interest in personalized health is a significant driver of growth in the microbiome sequencing service market. Individuals are becoming more proactive about their health, seeking personalized insights and solutions that align with their unique biological profiles. Direct-to-consumer microbiome testing services are gaining popularity, offering individuals the opportunity to explore their microbiome data and make informed health decisions.

Direct-to-consumer microbiome testing services have democratized access to personalized health insights. These services provide individuals with easy-to-understand reports on their microbiome composition, along with actionable recommendations for diet, lifestyle, and wellness. The growing availability and affordability of such tests are expanding market reach and driving consumer adoption.

Segmental Insights

Technology Insights

Based on Technology, Sequencing by synthesis (SBS) have emerged as the fastest growing segment in the Global Microbiome Sequencing Service Market in 2023. SBS technology, pioneered by companies like Illumina, has revolutionized the field of DNA sequencing. It involves synthesizing a complementary DNA strand from a template strand and incorporating labeled nucleotides that emit a signal when added. This process allows for real-time detection of nucleotide incorporation, providing highly accurate sequencing data. The continuous improvements in SBS technology have enhanced its efficiency, speed, and read length capabilities, making it a preferred choice for microbiome sequencing.

One of the primary reasons for the widespread adoption of SBS is its high accuracy and reliability. The technology's ability to produce high-quality data with low error rates is crucial for microbiome research, where precise identification of microbial species and their relative abundances is essential. Accurate sequencing is particularly important in studies aiming to uncover the links between microbial communities and human health, as even small errors can lead to significant misinterpretations.

SBS has become increasingly cost-effective, making it accessible to a broader range of researchers and institutions. The reduction in sequencing costs has been driven by advancements in technology, increased competition among sequencing providers, and economies of scale. As a result, SBS offers an attractive balance of high performance and affordability, enabling more extensive and in-depth microbiome studies within budget constraints.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The versatility of SBS technology has contributed to its rapid growth in the microbiome sequencing service market. SBS is used in a wide range of applications, including clinical diagnostics, environmental studies, agricultural research, and pharmaceutical development. In clinical settings, SBS is employed to investigate the role of the microbiome in various diseases, such as gastrointestinal disorders, metabolic conditions, and infectious diseases. In agriculture, SBS helps in understanding soil microbiomes and their impact on crop health and productivity. The broad applicability of SBS has expanded its market reach and driven demand across multiple sectors.

The integration of advanced bioinformatics tools and software with SBS has further accelerated its adoption. These tools enable efficient analysis and interpretation of the vast amounts of data generated by SBS, providing researchers with actionable insights into microbial communities. Enhanced data analysis capabilities facilitate the identification of biomarkers, functional pathways, and microbial interactions, thereby advancing our understanding of microbiomes and their implications for health and disease. Strategic collaborations and partnerships between sequencing technology providers, academic institutions, and research organizations have also played a significant role in the growth of SBS. These collaborations foster the development and optimization of SBS workflows, promote knowledge sharing, and drive innovation. By working together, stakeholders can address technical challenges, improve sequencing accuracy, and expand the applications of SBS technology.

Application Insights

Based on Application, Autoimmune Disorder have emerged as the dominating segment in the Global Microbiome Sequencing Service Market during the forecast period. The human microbiome, comprising trillions of microorganisms residing in and on our bodies, plays a crucial role in maintaining immune homeostasis. Recent research has unveiled strong associations between microbiome imbalances and the onset of autoimmune disorders. Conditions such as rheumatoid arthritis, multiple sclerosis, lupus, and type 1 diabetes have been linked to dysbiosis, a state of microbial imbalance, which can trigger or exacerbate autoimmune responses.

This growing understanding has fueled interest in microbiome sequencing as a tool to explore these connections. By analyzing the composition and function of microbial communities in individuals with autoimmune disorders, researchers aim to identify specific microbial signatures associated with these conditions. This, in turn, drives the demand for comprehensive microbiome sequencing services that can provide detailed and accurate insights into microbial ecosystems.

The rapid advancement of sequencing technologies has significantly enhanced our ability to study the microbiome in the context of autoimmune diseases. Next-generation sequencing (NGS), metagenomics, and other high-throughput sequencing methods allow for in-depth analysis of microbial DNA, revealing the diversity and functional potential of microbial communities. These technologies have revolutionized microbiome research, providing researchers with the tools needed to investigate the complex interactions between the microbiome and the immune system.

For example, NGS enables the identification of microbial taxa that are either overrepresented or underrepresented in individuals with autoimmune disorders compared to healthy controls. Metagenomics provides insights into the metabolic pathways and functional capabilities of these microbial communities, helping to elucidate their roles in disease mechanisms. These advancements drive the demand for microbiome sequencing services as researchers seek to uncover the underlying microbial factors contributing to autoimmune diseases.

The rise of personalized medicine is another significant driver of the microbiome sequencing service market in the context of autoimmune disorders. Personalized medicine aims to tailor treatments based on individual genetic, environmental, and microbial profiles. As our understanding of the microbiome's influence on autoimmune diseases deepens, there is growing interest in developing targeted therapies that address specific microbial imbalances.

Microbiome sequencing is essential for identifying microbial targets and developing personalized interventions. By analyzing an individual's microbiome, healthcare providers can design tailored treatment plans that modulate the microbiome to restore balance and reduce autoimmune responses. This personalized approach not only improves treatment efficacy but also minimizes adverse effects, driving the demand for microbiome sequencing services.

The increasing prevalence of autoimmune disorders has led to numerous clinical and research collaborations aimed at understanding and treating these conditions. Partnerships between academic institutions, healthcare providers, and biotechnology companies facilitate large-scale studies and clinical trials that require extensive microbiome sequencing. These collaborations drive innovation and accelerate the translation of research findings into clinical practice.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Microbiome Sequencing Service Market in 2023. North America, particularly the United States and Canada, is home to some of the world's most advanced technological infrastructures in the field of life sciences. The region boasts numerous state-of-the-art research facilities, universities, and biotechnology companies that are at the forefront of microbiome research and sequencing technology.

The presence of cutting-edge sequencing platforms and high-throughput technologies enables rapid and accurate analysis of complex microbiome samples. Leading companies such as Illumina, Thermo Fisher Scientific, and others have their headquarters or major operations in North America, further consolidating the region's technological edge in the microbiome sequencing market. North America's dominance is also driven by significant investments in research and development (R&D). Federal agencies, private companies, and academic institutions invest heavily in microbiome research, aiming to explore the intricate relationships between microbial communities and human health, agriculture, and environmental sustainability.

Government initiatives such as the National Institutes of Health (NIH) in the United States provide substantial funding for microbiome research projects. This financial support fosters innovation and facilitates the development of new sequencing technologies, bioinformatics tools, and analytical methodologies that enhance the capabilities of microbiome sequencing services.

A robust regulatory environment in North America supports the growth and adoption of microbiome sequencing services.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and Health Canada play a crucial role in ensuring the safety, efficacy, and reliability of sequencing technologies and related applications.

The clear regulatory frameworks and guidelines provided by these agencies help streamline the development and commercialization of microbiome sequencing services. While the regulatory landscape is stringent, it offers a structured pathway for the introduction of new technologies and ensures high standards of quality and reliability, thereby fostering confidence among stakeholders.

North America's healthcare landscape is increasingly oriented towards personalized medicine, which emphasizes tailored treatment approaches based on individual genetic and microbiome profiles. Microbiome sequencing plays a critical role in this paradigm by providing insights into the composition and function of microbial communities that can influence health and disease.

Key Market Players

- Microbiome Insights
- BaseClear BV
- Clinical Microbiomics A/S
- Merieux NutriSciences Corporation
- MR DNA (Molecular Research LP)
- Prescient Medicine Holdings, Inc.
- Rancho Biosciences LLC
- Second Genome Inc.
- Zymo Research Corporation
- uBiome, Inc.

Report Scope:

In this report, the Global Microbiome Sequencing Service Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

□□ Microbiome Sequencing Service Market, By Technology:

- o Sequencing by synthesis
- o Sequencing by ligation
- o Sanger sequencing
- o Others

□□ Microbiome Sequencing Service Market, By Application:

- o Autoimmune Disorder
- o Cancer
- o Gastrointestinal Disorders

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

o Others

☐☐ Microbiome Sequencing Service Market, By Region:

o North America

☐ United States

☐ Canada

☐ Mexico

o Europe

☐ France

☐ United Kingdom

☐ Italy

☐ Germany

☐ Spain

o Asia Pacific

☐ China

☐ India

☐ Japan

☐ Australia

☐ South Korea

o South America

☐ Brazil

☐ Argentina

☐ Colombia

o Middle East & Africa

☐ South Africa

☐ Saudi Arabia

☐ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Microbiome Sequencing Service Market.

Available Customizations:

Global Microbiome Sequencing Service Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

☐☐ Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
- 3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
- 4. Impact of COVID-19 on Global Microbiome Sequencing Service Market
- 5. Global Microbiome Sequencing Service Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Technology (Sequencing by synthesis, Sequencing by ligation, Sanger sequencing, Others)
 - 5.2.2. By Application (Autoimmune Disorder, Cancer, Gastrointestinal Disorders, Others)
 - 5.2.3. By Region
 - 5.2.4. By Company (2023)
 - 5.3. Market Map
- 6. Asia Pacific Microbiome Sequencing Service Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Technology
 - 6.2.2. By Application
 - 6.2.3. By Country
 - 6.3. Asia Pacific: Country Analysis
 - 6.3.1. China Microbiome Sequencing Service Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Technology
 - 6.3.1.2.2. By Application
 - 6.3.2. India Microbiome Sequencing Service Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Technology
 - 6.3.2.2.2. By Application
 - 6.3.3. Australia Microbiome Sequencing Service Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Technology
 - 6.3.3.2.2. By Application
 - 6.3.4. Japan Microbiome Sequencing Service Market Outlook
 - 6.3.4.1. Market Size & Forecast
 - 6.3.4.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.4.2. Market Share & Forecast
 - 6.3.4.2.1. By Technology
 - 6.3.4.2.2. By Application
- 6.3.5. South Korea Microbiome Sequencing Service Market Outlook
 - 6.3.5.1. Market Size & Forecast
 - 6.3.5.1.1. By Value
 - 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Technology
 - 6.3.5.2.2. By Application
- 7. Europe Microbiome Sequencing Service Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Technology
 - 7.2.2. By Application
 - 7.2.3. By Country
 - 7.3. Europe: Country Analysis
 - 7.3.1. France Microbiome Sequencing Service Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Technology
 - 7.3.1.2.2. By Application
 - 7.3.2. Germany Microbiome Sequencing Service Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Technology
 - 7.3.2.2.2. By Application
 - 7.3.3. Spain Microbiome Sequencing Service Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Technology
 - 7.3.3.2.2. By Application
 - 7.3.4. Italy Microbiome Sequencing Service Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Technology
 - 7.3.4.2.2. By Application
 - 7.3.5. United Kingdom Microbiome Sequencing Service Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Technology
 - 7.3.5.2.2. By Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8. North America Microbiome Sequencing Service Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Technology
 - 8.2.2. By Application
 - 8.2.3. By Country
 - 8.3. North America: Country Analysis
 - 8.3.1. United States Microbiome Sequencing Service Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Technology
 - 8.3.1.2.2. By Application
 - 8.3.2. Mexico Microbiome Sequencing Service Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Technology
 - 8.3.2.2.2. By Application
 - 8.3.3. Canada Microbiome Sequencing Service Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Technology
 - 8.3.3.2.2. By Application
- 9. South America Microbiome Sequencing Service Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Technology
 - 9.2.2. By Application
 - 9.2.3. By Country
 - 9.3. South America: Country Analysis
 - 9.3.1. Brazil Microbiome Sequencing Service Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Technology
 - 9.3.1.2.2. By Application
 - 9.3.2. Argentina Microbiome Sequencing Service Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Technology
 - 9.3.2.2.2. By Application
 - 9.3.3. Colombia Microbiome Sequencing Service Market Outlook

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Technology
 - 9.3.3.2.2. By Application
- 10. Middle East and Africa Microbiome Sequencing Service Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Technology
 - 10.2.2. By Application
 - 10.2.3. By Country
 - 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Microbiome Sequencing Service Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Technology
 - 10.3.1.2.2. By Application
 - 10.3.2. Saudi Arabia Microbiome Sequencing Service Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Technology
 - 10.3.2.2.2. By Application
 - 10.3.3. UAE Microbiome Sequencing Service Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Technology
 - 10.3.3.2.2. By Application
- 11. Market Dynamics
 - 11.1. Drivers
 - 11.2. Challenges
- 12. Market Trends & Developments
 - 12.1. Recent Developments
 - 12.2. Product Launches
 - 12.3. Mergers & Acquisitions
- 13. Global Microbiome Sequencing Service Market: SWOT Analysis
- 14. Porter's Five Forces Analysis
 - 14.1. Competition in the Industry
 - 14.2. Potential of New Entrants
 - 14.3. Power of Suppliers
 - 14.4. Power of Customers
 - 14.5. Threat of Substitute Product
- 15. Competitive Landscape
 - 15.1. Microbiome Insights

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.2. BaseClear BV
- 15.3. Clinical Microbiomics A/S
- 15.4. Merieux NutriSciences Corporation
- 15.5. MR DNA (Molecular Research LP)
- 15.6. Prescient Medicine Holdings, Inc.
- 15.7. Rancho Biosciences LLC
- 15.8. Second Genome Inc.
- 15.9. Zymo Research Corporation
- 15.10. uBiome, Inc.
- 16. Strategic Recommendations
- 17. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Microbiome Sequencing Service Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing by synthesis, Sequencing by ligation, Sanger sequencing, Others), By Application (Autoimmune Disorder, Cancer, Gastrointestinal Disorders, Others), By Region and Competition, 2019-2029F

Market Report | 2024-08-02 | 185 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	<input type="text"/>